Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous umbilical cord blood-derived mononuclear cells
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
This investigational cell-based therapy consists of autologous umbilical cord blood-derived mononuclear cells (UCB-MNCs) developed by Dr. Timothy J. Nelson and the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome at Mayo Clinic. The therapy involves collecting umbilical cord blood from infants diagnosed with hypoplastic left heart syndrome (HLHS) at birth, processing it to isolate mononuclear stem cells, and delivering them via intramyocardial injection into the right ventricular myocardium during Stage II palliation surgery (Glenn procedure), typically performed at 3-13 months of age. The goal is to strengthen the underdeveloped right ventricle through regenerative medicine. However, a Phase IIb multicenter trial (AutoCell-S2) involving 95 children found that the treatment failed to enhance cardiac function and was associated with unfavorable changes in longitudinal cardiac strain and higher rates of serious adverse events compared to controls.
- Other names
- UCB-MNCsautologous mononuclear cells derived from umbilical cord blood
Beyond the preview
Go deeper on autologous umbilical cord blood-derived mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous umbilical cord blood-derived mononuclear cells.